FindTrial
Sign In

A medical records based study for KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1

KLK8 promotes the proliferation and metastasis of colorectal cancer via the activation of EMT associated with PAR1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048646
Enrollment
Unknown
Registered
2021-07-12
Start date
2021-07-12
Completion date
Unknown
Last updated
2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Case series:No

Sponsors

Cancer Hospital of Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The inclusion criteria for colorectal cancer patients were as follows: 1) Two pathologists diagnosed colorectal adenocarcinoma; 2) Colorectal cancer is primary cancer; 3) The clinical stage and pathological information were complete; 4) The patients were divided into stage I - VI (according to the eighth edition of American Cancer Association (AJCC) tumor staging guidelines); 5) No preoperative chemoradiotherapy or neoadjuvant therapy was given.

Exclusion criteria

Exclusion criteria: Operations performed by other surgeons

Design outcomes

Primary

MeasureTime frame
KLK8 protein concentration;—

Contacts

Public ContactPingbo Xu

Cancer Hospital of Fudan University

xupingboshanghai@163.com18017312996

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026